Imodium

Loperamide Hydrochloride, the active ingredient in Imodium, is a peripheral μ‑opioid receptor agonist presented as an oral tablet for oral use. It reduces intestinal motility and enhances water absorption, helping to control acute nonspecific diarrhea, chronic diarrhea, and irritable bowel syndrome with diarrhea in adults.

GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across multiple markets, and our distribution network includes major procurement platforms and direct contracts, facilitating reliable access to essential antidiarrheal therapy.

Imodium is used to manage diarrheal conditions by slowing intestinal transit and increasing fluid absorption. - Acute nonspecific diarrhea: decreases stool frequency and liquidity, helping patients achieve faster symptom resolution. - Chronic diarrhea: provides ongoing control of bowel movements when other causes have been excluded. - Irritable bowel syndrome with diarrhea (IBS‑D): alleviates frequent loose stools and abdominal discomfort associated with the condition. - Travelers’ diarrhea: offers short‑term relief of loose stools during short trips or exposure to unfamiliar pathogens. - Chemotherapy‑induced diarrhea: helps manage mild to moderate diarrhea in patients undergoing cancer treatment.

Loperamide may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Constipation: hard stools or difficulty passing stool, which may require laxative use if persistent. - Abdominal cramps: mild to moderate cramping in the abdomen, often occurring shortly after dosing. - Nausea: feeling of queasiness that usually resolves without intervention. - Dizziness: light‑headed sensation that may be more noticeable when standing quickly.

Serious or Rare Side Effects: - Severe constipation or bowel obstruction: risk of impaction requiring medical attention, potentially leading to abdominal pain and vomiting. - Allergic reactions: rash, itching, swelling, or anaphylaxis that necessitates immediate discontinuation and medical care. - Cardiac effects: abnormal heart rhythm or QT interval prolongation, especially in patients with pre‑existing heart conditions or when combined with interacting drugs. - Toxic megacolon: rare but life‑threatening dilation of the colon that presents with severe abdominal distension and systemic toxicity.

When using Imodium, certain precautions should be observed to ensure safe and effective therapy. - Indication verification: confirm diarrhea is not caused by infection or inflammatory disease before use. - Dosage limits: do not exceed recommended daily amount set by the prescriber. - Dehydration risk: maintain adequate fluid intake to prevent dehydration, especially in children and the elderly. - Underlying conditions: avoid use in patients with known hypersensitivity to loperamide or opioid agents. - Concomitant medications: review all current drugs for potential interactions, particularly those affecting cardiac conduction. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Loperamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase systemic loperamide levels and risk of cardiac toxicity. - P-glycoprotein inhibitors (e.g., quinidine, verapamil): can raise plasma concentrations, heightening adverse effects. - Other opioid agonists: additive central opioid effects may occur despite peripheral action.

Moderate Interactions (Monitor Closely): - Antidiarrheal agents (e.g., diphenoxylate): combined use may cause excessive slowing of gut motility. - Anticholinergic drugs: may enhance constipation. - QT‑prolonging drugs (e.g., macrolide antibiotics): monitor cardiac rhythm when co‑administered.